Ulcerative Colitis-associated Spondyloarthritis Successfully Treated with Infliximab in the Absence of Enhanced TNF-α Responses

Although concurrent occurrence of spondyloarthritis (SpA) and ulcerative colitis (UC) is sometimes seen, the profiles of cytokines have been poorly understood in UC-associated SpA. We herein report a case of UC-associated SpA successfully treated with infliximab (IFX). Profiles of cytokines in the s...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2023/09/01, Vol.62(17), pp.2493-2497
Main Authors: Fujita, Shunsuke, Honjo, Hajime, Takada, Ryutaro, Hara, Akane, Masuta, Yasuhiro, Otsuka, Yasuo, Handa, Kohei, Minaga, Kosuke, Tsuji, Shigeyoshi, Kudo, Masatoshi, Watanabe, Tomohiro
Format: Article
Language:English
Subjects:
Arthritis
Case Report
Case reports
IL-6
Inflammatory diseases
Infliximab
Interleukin 6
Internal medicine
Monoclonal antibodies
Remission
Rheumatic diseases
spondyloarthritis
TNF-α
Tumor necrosis factor-α
Ulcerative colitis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although concurrent occurrence of spondyloarthritis (SpA) and ulcerative colitis (UC) is sometimes seen, the profiles of cytokines have been poorly understood in UC-associated SpA. We herein report a case of UC-associated SpA successfully treated with infliximab (IFX). Profiles of cytokines in the serum and colonic mucosa were characterized by an enhanced expression of IL-6 but not tumor necrosis factor (TNF)-α. Successful induction of remission by IFX was associated with the downregulation of IL-6 expression but no significant alteration in TNF-α expression. These findings suggest that some cases of UC-associated SpA might be driven by IL-6, and IFX might be effective in cases lacking enhanced TNF-α responses.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.1182-22